Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control
The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled prostate-specific membrane antigen (PSMA)-617 therapy in a retrospectively analyzed group of patients.
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
Jan. 11, 2018
|
| In: |
Journal of nuclear medicine
Year: 2018, Jahrgang: 59, Heft: 5, Pages: 795-802 |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.117.203539 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.2967/jnumed.117.203539 Verlag, lizenzpflichtig, Volltext: http://jnm.snmjournals.org/content/59/5/795 |
| Verfasserangaben: | Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Markus Hohenfellner, Frederik L. Giesel, Uwe Haberkorn, and Alfred Morgenstern |
| Zusammenfassung: | The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled prostate-specific membrane antigen (PSMA)-617 therapy in a retrospectively analyzed group of patients. |
|---|---|
| Beschreibung: | Im Titel erscheint die Ziffernfolge 225 hochgestellt Gesehen am 16.04.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.117.203539 |